GB0516379D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB0516379D0
GB0516379D0 GBGB0516379.5A GB0516379A GB0516379D0 GB 0516379 D0 GB0516379 D0 GB 0516379D0 GB 0516379 A GB0516379 A GB 0516379A GB 0516379 D0 GB0516379 D0 GB 0516379D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0516379.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0516379.5A priority Critical patent/GB0516379D0/en
Publication of GB0516379D0 publication Critical patent/GB0516379D0/en
Priority to PCT/EP2006/007875 priority patent/WO2007017264A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0516379.5A 2005-08-09 2005-08-09 Compounds Ceased GB0516379D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0516379.5A GB0516379D0 (en) 2005-08-09 2005-08-09 Compounds
PCT/EP2006/007875 WO2007017264A2 (en) 2005-08-09 2006-08-07 Pyrrolopyridinederivatives as modulators of the cannabinoid receptor for the treatment of immune and inflammatory disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0516379.5A GB0516379D0 (en) 2005-08-09 2005-08-09 Compounds

Publications (1)

Publication Number Publication Date
GB0516379D0 true GB0516379D0 (en) 2005-09-14

Family

ID=34984350

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0516379.5A Ceased GB0516379D0 (en) 2005-08-09 2005-08-09 Compounds

Country Status (2)

Country Link
GB (1) GB0516379D0 (en)
WO (1) WO2007017264A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110627846A (en) * 2019-10-30 2019-12-31 河南师范大学 Galactoside-tetrastyrene compound, preparation method thereof and application thereof as drug carrier

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010002712A (en) 2007-09-10 2010-06-09 Calcimedica Inc Compounds that modulate intracellular calcium.
HUE043555T2 (en) 2007-11-30 2019-09-30 Zynerba Pharmaceuticals Inc Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
WO2009076454A2 (en) * 2007-12-12 2009-06-18 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP5782377B2 (en) * 2008-08-27 2015-09-24 カルシメディカ，インク． Compounds that regulate intracellular calcium
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
RU2011143740A (en) 2009-03-30 2013-05-10 Астеллас Фарма Инк. Compound pyrimidine
EP2477982A4 (en) 2009-09-16 2013-04-03 Calcimedica Inc Compounds that modulate intracellular calcium
JP5776691B2 (en) 2010-07-29 2015-09-09 アステラス製薬株式会社 Fused pyridine compound
CN104995173A (en) * 2012-11-30 2015-10-21 协和发酵麒麟株式会社 Nitrogen-containing heterocyclic compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399791A1 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
GB0017256D0 (en) * 2000-07-13 2000-08-30 Merck Sharp & Dohme Therapeutic agents
TW200522944A (en) * 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
WO2005121140A1 (en) * 2004-06-09 2005-12-22 Glaxo Group Limited Pyrrolopyridine derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110627846A (en) * 2019-10-30 2019-12-31 河南师范大学 Galactoside-tetrastyrene compound, preparation method thereof and application thereof as drug carrier
CN110627846B (en) * 2019-10-30 2022-11-29 河南师范大学 Galactoside-tetrastyrene compound, preparation method thereof and application thereof as drug carrier

Also Published As

Publication number Publication date
WO2007017264A3 (en) 2007-04-12
WO2007017264A2 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
GB0508472D0 (en) Compounds
GB0503962D0 (en) Compounds
GB0507602D0 (en) Compounds
GB0502418D0 (en) Compounds
GB0502316D0 (en) Compounds
EP1961741A4 (en) m-CARBAZOLYLPHENYL COMPOUNDS
GB0508463D0 (en) Compounds
GB0502299D0 (en) Compounds
GB0502310D0 (en) Compounds
GB0516379D0 (en) Compounds
AP2007004220A0 (en) Motilide compounds
GB0505084D0 (en) Compounds
EP1907385A4 (en) Compounds
GB0506467D0 (en) Compounds
GB0505086D0 (en) Compounds
GB0508460D0 (en) Compounds
GB0505509D0 (en) Compounds
GB0505735D0 (en) Compounds
GB0501985D0 (en) Compounds
EP1867650A4 (en) Hydroxymethylboron compounds
GB0505085D0 (en) Compounds
GB0501984D0 (en) Compounds
GB0503145D0 (en) Compounds
GB0500891D0 (en) Compounds
GB0509204D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)